# Clinical Trial to Evaluate the Efficacy of Probit-Based Triple Therapy for Helicobacter Pylori Eradication

> **NCT07115173** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Samsung Medical Center** · enrollment: 103 (estimated)

## Conditions studied

- Helicobacter Infection

## Interventions

- **DRUG:** This study aims to evaluate the efficacy and safety of a 14-day triple therapy regimen consisting of Zastaprazan 20 mg, clarithromycin, and amoxicillin for the eradication of Helicobacter pylori.

## Key facts

- **NCT ID:** NCT07115173
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-12-31
- **Target enrollment:** 103 (ESTIMATED)
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07115173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07115173, "Clinical Trial to Evaluate the Efficacy of Probit-Based Triple Therapy for Helicobacter Pylori Eradication". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07115173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*